Brigitte Autran

Summary

Country: France

Publications

  1. ncbi Therapeutic vaccines for chronic infections
    Brigitte Autran
    Laboratoire d Immunologie Cellulaire and INSERM Unit 543, Centre Hospitalier Universitaire Pitie Salpetriere, Universite Pierre et Marie Curie, 75013 Paris, France
    Science 305:205-8. 2004
  2. ncbi Evaluating therapeutic vaccines in patients infected with HIV
    Brigitte Autran
    Laboratoire d Immunologie Cellulaire and INSERM U 543, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Expert Rev Vaccines 3:S169-77. 2004
  3. ncbi Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
    Sabine Kinloch-de Loes
    Department of Medicine, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 192:607-17. 2005
  4. ncbi Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets
    Bruno Salaun
    Division of Clinical Onco Immunology, Ludwig Center for Cancer Research of the University of Lausanne, Switzerland
    J Transl Med 9:44. 2011
  5. ncbi T-cell and serological responses to Erp, an exported Mycobacterium tuberculosis protein, in tuberculosis patients and healthy individuals
    Valerie Martinez
    Laboratoire d Immunologie Cellulaire, INSERM U543, Hopital Pitie Salpetriere, Paris Cedex 13, France
    BMC Infect Dis 7:83. 2007
  6. ncbi Elite controllers as a model of functional cure
    Brigitte Autran
    Laboratory Immunity and Infection, Pierre and Marie Curie University, INSERM UMRS 945, France
    Curr Opin HIV AIDS 6:181-7. 2011
  7. ncbi Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)
    Brigitte Autran
    UPMC Univ Paris 06, UMR_543, France
    AIDS 22:1313-22. 2008
  8. ncbi Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells
    Benjamin Descours
    Immunity and Infection Laboratory, Pierre and Marie Curie University, INSERM UMRS 945, Pitie Salpetriere Hospital, Paris, France
    Clin Infect Dis 54:1495-503. 2012
  9. ncbi Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy
    Amelie Guihot
    UPMC Univ Paris 06, INSERM, UMR945, AP HP, Laboratoire d Immunologie Cellulaire et Tissulaire, Hopital Pitie Salpetriere, Paris, France
    AIDS 24:614-7. 2010
  10. ncbi T cells subtypes in a patient with interferon-alpha induced sarcoidosis
    Jean Jacques Monsuez
    AP HP, Hopital Paul Brousse, Department of Internal Medicine, Universite Paris Sud 11, Faculté de Médecine de Bicêtre, Villejuif Cedex, France
    Am J Med Sci 337:60-2. 2009

Detail Information

Publications54

  1. ncbi Therapeutic vaccines for chronic infections
    Brigitte Autran
    Laboratoire d Immunologie Cellulaire and INSERM Unit 543, Centre Hospitalier Universitaire Pitie Salpetriere, Universite Pierre et Marie Curie, 75013 Paris, France
    Science 305:205-8. 2004
    ....
  2. ncbi Evaluating therapeutic vaccines in patients infected with HIV
    Brigitte Autran
    Laboratoire d Immunologie Cellulaire and INSERM U 543, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Expert Rev Vaccines 3:S169-77. 2004
    ..The design and end-points of clinical trials, and the clinical settings in which these new strategies should be evaluated and will be of benefit, have yet to be defined and are the focus of this review...
  3. ncbi Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
    Sabine Kinloch-de Loes
    Department of Medicine, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 192:607-17. 2005
    ..Our trial design appears to be feasible and safe for testing future immune-boosting strategies...
  4. ncbi Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets
    Bruno Salaun
    Division of Clinical Onco Immunology, Ludwig Center for Cancer Research of the University of Lausanne, Switzerland
    J Transl Med 9:44. 2011
    ..MicroRNAs have been recently shown to play a key role in the regulation of haematopoiesis in mouse, but their implication in peripheral lymphocyte differentiation in humans remains largely unknown...
  5. ncbi T-cell and serological responses to Erp, an exported Mycobacterium tuberculosis protein, in tuberculosis patients and healthy individuals
    Valerie Martinez
    Laboratoire d Immunologie Cellulaire, INSERM U543, Hopital Pitie Salpetriere, Paris Cedex 13, France
    BMC Infect Dis 7:83. 2007
    ..Cellular and humoral immune responses to Erp (Exported repetitive protein)--a recently identified M. tuberculosis protein--have not yet been investigated in humans and may contribute to this aim...
  6. ncbi Elite controllers as a model of functional cure
    Brigitte Autran
    Laboratory Immunity and Infection, Pierre and Marie Curie University, INSERM UMRS 945, France
    Curr Opin HIV AIDS 6:181-7. 2011
    ....
  7. ncbi Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)
    Brigitte Autran
    UPMC Univ Paris 06, UMR_543, France
    AIDS 22:1313-22. 2008
    ..Evaluate immunogenicity and clinical efficacy of two immunization strategies with the ALVAC-HIV-recombinant canarypox vaccine (vCP1452) in treated HIV-infected patients...
  8. ncbi Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells
    Benjamin Descours
    Immunity and Infection Laboratory, Pierre and Marie Curie University, INSERM UMRS 945, Pitie Salpetriere Hospital, Paris, France
    Clin Infect Dis 54:1495-503. 2012
    ....
  9. ncbi Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy
    Amelie Guihot
    UPMC Univ Paris 06, INSERM, UMR945, AP HP, Laboratoire d Immunologie Cellulaire et Tissulaire, Hopital Pitie Salpetriere, Paris, France
    AIDS 24:614-7. 2010
    ..Long-term and efficient antiretroviral therapy provides continuous benefits both on the immune system and on the HIV reservoirs...
  10. ncbi T cells subtypes in a patient with interferon-alpha induced sarcoidosis
    Jean Jacques Monsuez
    AP HP, Hopital Paul Brousse, Department of Internal Medicine, Universite Paris Sud 11, Faculté de Médecine de Bicêtre, Villejuif Cedex, France
    Am J Med Sci 337:60-2. 2009
    ..This activation process also improved over time, but more slowly than clinical symptoms...
  11. ncbi Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients
    Ana Canestri
    AP HP, Hopital Pitie Salpetriere, Service des Maladies Infectieuses et Tropicales, Paris, France
    AIDS 24:2887-9. 2010
    ..Seroprotection, seroconversion, and geometric mean titer ratio of specific antibody titers did not differ between groups. These results suggest that maraviroc does not significantly affect the immune response to this adjuvanted vaccine...
  12. ncbi [HIV controllers: a new evolutionary entity of HIV infection?]
    Valerie Martinez
    Laboratoire d Immunologie Cellulaire et Tissulaire, Universite Pierre et Marie Curie Paris 6, Paris, France
    Med Sci (Paris) 24:7-9. 2008
  13. ncbi Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006
    Florence Damond
    APHP, Hopital Bichat Claude Bernard, Laboratoire de Virologie, Paris, 75018 France
    J Clin Microbiol 46:2088-91. 2008
    ..Quantification varied between laboratories, and international standardization of quantification assays is strongly needed...
  14. ncbi Demographic and clinical factors associated with response to smallpox vaccine in preimmunized volunteers
    Philippe Bossi
    Department of Infectious Diseases, University Pierre and Marie Curie, Paris VI, Paris, France
    PLoS ONE 3:e4087. 2008
    ..This program included the establishment of a preoutbreak national team that could be revaccinated against smallpox...
  15. ncbi Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus
    Amelie Guihot
    UPMC Univ Paris 06, INSERM, UM 5945, AP HP, Hopital Pitie Salpetriere, Immunitiet infection F 75013, Paris, France
    Trends Immunol 32:131-7. 2011
    ..Immune restoration during HAART can, however, have adverse effects. Immune restoration syndrome occurs in some patients as a result of successful but unbalanced immunity...
  16. ncbi Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)
    Roland Tubiana
    , INSERM E0214, , Paris, France
    Vaccine 23:4292-301. 2005
    ..Detection of such LPR response at the time of treatment interruption was significantly associated with the probability of remaining off therapy. These results provide rationale for future randomized trials exploring this strategy...
  17. ncbi Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV
    François Boutboul
    Laboratoire d Immunologie Cellulaire, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    AIDS 19:1981-6. 2005
    ....
  18. ncbi Proliferative, IFNgamma and IL-2-producing T-cell responses to HIV-2 in untreated HIV-2 infection
    Nadia Alatrakchi
    Laboratoire d'Immunologie Cellulaire, INSERM U.543, , Paris, France
    AIDS 20:29-34. 2006
    ..In addition, lymphoproliferative responses to HIV-2 were associated with lack of viral replication...
  19. ncbi Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients
    Anne Bourgarit
    Laboratory of Cellular Immunology, Pitie-Salpetriere Hospital, , Paris, France
    AIDS 20:F1-7. 2006
    ..CONCLUSION: An acute exacerbation of Th1 responses against mycobacterial antigens appears to cause IRS in patients co-infected with HIV and TB. This key event provides new evidence valuable for the diagnosis and treatment of IRS...
  20. ncbi Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity
    Martine Braibant
    Laboratoire de Virologie, , INSERM ERI 19, 37044 Tours Cedex, France
    AIDS 20:1923-30. 2006
    ..CONCLUSION: These results suggest that the antigenicity of the "silent face" of gp120 that exposes the 2G12 epitope should be analysed in more detail, to find ways to induce broadly neutralizing antibodies...
  21. ncbi Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma
    Amelie Guihot
    Laboratoire d'Immunologie Cellulaire et Tissulaire du Pr. Debre, INSERM UMR S 543, Batiment CERVI, Hopital Pitie-Salpetriere, 47 Bd de l'Hopital, 75013, Paris, France
    J Infect Dis 194:1078-88. 2006
    ..Also, we have described 8 new HHV-8 T cell epitopes in LANA-1, K12, and K15, including 2 CD4 T cell epitopes. These data provide new insight into HHV-8 cellular immunity...
  22. ncbi Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease
    Assia Samri
    Laboratoire d Immunologie Cellulaire, AP HP, Hopital Pitie Salpetriere, Paris, France
    Antivir Ther 12:553-8. 2007
    ..The long-term immunological benefit of protease inhibitor (PI)-sparing antiretroviral therapy (ART) using non-nucleoside reverse transcriptase inhibitors (NNRTIs) remains poorly investigated...
  23. ncbi Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression
    Valerie Martinez
    Laboratoire d Immunologie Cellulaire et Tissulaire, INSERM U543, Universite Pierre et Marie Curie, Hopital Pitie Salpetriere, Paris, France
    J Infect Dis 191:2053-63. 2005
    ....
  24. ncbi High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease
    Jean Gabarre
    Service d Hematologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
    Haematologica 89:1100-8. 2004
    ....
  25. ncbi Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection
    Cécile Chouquet
    INSERM EMI 0214, Laboratoire d Immunologie Cellulaire et Tissulaire, Centre Hospitalier Pitié Salpétrière, Institut Pasteur, 25 rue du Dr Roux, 75015 Paris, France
    AIDS 16:2399-407. 2002
    ..The correlations between the breadth and specificities of memory CTL and virus production and disease progression are still unknown, but are of major importance for vaccine strategies...
  26. ncbi Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082
    Christine Katlama
    Service for Infectious and Tropical Diseases, Paris, France
    AIDS 16:2027-34. 2002
    ..CONCLUSIONS: Administration of interleukin-2 produces significant and sustained increase in CD4 cell counts in HAART-treated patients with persistent CD4 cell counts < 200 x 10(6) cells/l...
  27. ncbi A patient with HIV-1 superinfection
    Stephanie Jost
    Division of Infectious Diseases, University of Geneva, Geneva
    N Engl J Med 347:731-6. 2002
  28. ncbi Therapeutic vaccines against HIV need international partnerships
    Brigitte Autran
    Laboratoire d Immunologie Cellulaire, Centre Hospitalier Universitaire Pitie Salpetriere, 75651 Paris, France
    Nat Rev Immunol 3:503-8. 2003
    ....
  29. ncbi Strategies toward restoration of immunity to HIV
    Brigitte Autran
    AIDS 16:4-6. 2002
  30. ncbi Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial)
    Constance Delaugerre
    Department of Virology-EA2387, , Paris, France
    Antivir Ther 8:233-7. 2003
    ..CONCLUSION: Administration of IL-2 combined with HAART in HIV-1 infected-patients with advanced disease led to an increase of HIV-1 pro-viral DNA per million PBMC without virological failure or emergence of resistance...
  31. ncbi IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia
    Guislaine Carcelain
    Laboratoire d'Immunologie Cellulaire, INSERM U543, Paris, France
    AIDS 17:841-50. 2003
    ..CONCLUSION: Although we cannot rule out a mechanism of altered proliferation or death rate, the thymus plays an important role in the long-term recovery of naive T cells under IL-2 therapy...
  32. ncbi Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection
    Nadia Alatrakchi
    Laboratoire d'Immunologie Cellulaire et Tissulaire INSERM U543, , Paris, France
    AIDS 18:121-3. 2004
    ..This suggests that IFN+R therapy might compromise virus-specific immune defenses in immunosuppressed patients...
  33. ncbi Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus
    Nadia Alatrakchi
    Laboratoire d'Immunologie Cellulaire, , Paris, France
    AIDS 16:713-7. 2002
    ..006). CONCLUSION: Thus, independently of the HIV-related immune alterations, LT-NP of the HIV-infection might have an intrinsic capacity to develop strong Th1 cell responses to viruses, particularly HIV and HCV...
  34. ncbi Plasticity of lymphoid compartments during HIV infection and treatments: hopes and limits
    Behazine Combadiere
    Laboratoire d Immunologie Cellulaire et Tissulaire, Unité Inserm 543, Hopital Pitie Salpetriere, 83, Boulevard de l Hopital, 75013 Paris, France
    Microbes Infect 4:575-80. 2002
    ....
  35. ncbi The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients
    Behazine Combadiere
    INSERM U543, Laboratoire d Immunologie Cellulaire, Faculté de Médecine Pitié Salpêtière, Paris, France
    AIDS 17:1279-90. 2003
    ..In order to understand the mechanism by which CX3CR1 participates in the regulation of HIV-immune responses, we investigated its expression and role on T lymphocytes in HIV-infected patients...
  36. ncbi A triple-mutated allele of granzyme B incapable of inducing apoptosis
    Dorian McIlroy
    Laboratoire d'Immunologie Cellulaire et Tissulaire, , , 75013 Paris, France
    Proc Natl Acad Sci U S A 100:2562-7. 2003
    ....
  37. ncbi Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans
    Annika Vogt
    Clinical Research Center for Hair and Skin Physiology, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Chariteplatz 1, Berlin, Germany
    J Immunol 180:1482-9. 2008
    ..This study proposes new perspectives for the development of vaccination strategies that trigger T cell immune responses in humans...
  38. ncbi Differential requirement of caspases during naive T cell proliferation
    Alexandre Boissonnas
    , Laboratoire d'Immunologie Cellulaire, INSERM U543, , F-75643 Paris Cedex 13, France
    Eur J Immunol 32:3007-15. 2002
    ..These data reveal a novel facet of antigenic caspase regulation during naive CD4 T cell proliferation and provide insights into the function of caspases during T cell homeostasis...
  39. ncbi T-cell subset counting and the fight against AIDS: reflections over a 20-year struggle
    Francis Mandy
    National HIV Immunology Laboratory, Health Canada, LCDC 0603B1, Tunney s Pasture, Ottawa, Ontario K1A 0L2, Canada
    Cytometry 50:39-45. 2002
    ..It is clear that an effective attack on the human immunodeficiency virus (HIV) epidemic has to embrace resource-poor regions. Reducing the cost of the assay while improving reliability and durability is a move in the right direction...
  40. ncbi Cell permeabilization for the assessment of T lymphocyte polyfunctional capacity
    Laura Papagno
    Cellular Immunology Laboratory, INSERM U543, Avenir Group, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie PARIS6, Paris, France
    J Immunol Methods 328:182-8. 2007
    ..It is important to be aware of this potential bias and to design specific application/experimental procedures in order to obtain optimal results...
  41. ncbi Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover
    Jorge R Almeida
    Cellular Immunology Laboratory, U543, Institut National de la Sante et de la Recherche Medicale, Avenir Group, 75013 Paris, France
    J Exp Med 204:2473-85. 2007
    ..Such attributes are interlinked and constitute the basis for effective control of HIV-1 replication. These data on the features of effective CD8+ T cells in HIV infection may aid in the development of successful T cell vaccines...
  42. ncbi Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease
    Karim Sacre
    Laboratoire d'Immunologie Cellulaire et Tissulaire, INSERM U543, , , 75013 Paris, France
    J Exp Med 201:1999-2010. 2005
    ....
  43. ncbi Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans
    Behazine Combadiere
    Laboratoire d'Immunologie Cellulaire, INSERM U543, Paris, France
    J Exp Med 199:1585-93. 2004
    ..Such long-term maintenance of vaccinia-specific immune memory in the absence of smallpox virus modifies our understanding of the mechanism of persistence of long-term memory to poxviruses and challenges vaccination strategies...
  44. ncbi A simplified flow cytometry method of CD4 and CD8 cell counting based on thermoresistant reagents: implications for large scale monitoring of HIV-infected patients in resource-limited settings
    Silva Barbesti
    BIO-D Srl, Valenzano, Italy
    Cytometry B Clin Cytom 68:43-51. 2005
    ..The reagents can be stored under unfavorable environmental conditions for long period of time. These features should facilitate access to flow cytometry testing in resource-poor settings...
  45. ncbi Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs
    Yasuko Tsunetsugu-Yokota
    Department of Immunology, National Institute of Infectious Diseases, Shinjuku ku, Japan
    J Virol 77:10250-9. 2003
    ....
  46. ncbi Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of tumour necrosis factor-alpha and nitric oxide synthase
    Jay A Levy
    AIDS 17:1119. 2003
  47. ncbi No influence of human herpesvirus 8 infection on the progression of HIV-1 infection in initially asymptomatic patients
    Zaina Ait-Arkoub
    Department of aVirology EA 2387, Paris, France
    AIDS 17:1394-6. 2003
  48. ncbi [Evaluation of residual immune response against human pox virus before and after revaccination in healthy volunteers]
    Francois Bricaire
    Service des Maladies Infectieuses et Tropicales, G H Pitié Salpêtrière, 47 83 boulevard de l Hopital, 75013 Paris
    Bull Acad Natl Med 190:1035-46; discussion 1046-9. 2006
    ..Three-quarters of the subjects had a proliferative response. This response was lower after the age of 55 years but could be reactivated by revaccination...
  49. ncbi Trapping and apoptosis of novel subsets of memory T lymphocytes expressing CCR6 in the spleen of HIV-infected patients
    Cedric Lecureuil
    INSERM U543, Assistance Publique Hopitaux de Paris, Faculte de Medecine, Universite Pierre et Marie Curie Paris 6, Paris, France
    Blood 109:3649-57. 2007
    ....
  50. ncbi Accelerated immune senescence and HIV-1 infection
    Victor Appay
    Laboratoire d Immunologie Cellulaire et Tissulaire, INSERM U543, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie Paris 6, Paris, France
    Exp Gerontol 42:432-7. 2007
    ..Similar observations have been done in HIV non-infected elderly individuals, which suggests that premature immunosenescence occurs in HIV-1 infection, as a result of persistent immune activation...
  51. ncbi Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro
    Emi E Nakayama
    Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, 3 1 Yamada oka, Suita Shi, Osaka, Japan
    Immunogenetics 59:511-5. 2007
    ..Our epidemiological and molecular biological findings clearly indicate H43Y has a very minor effect on anti-HIV-1 activity of TRIM5alpha, suggesting that this allele is immaterial, at least in HIV-1-infected Europeans and Asians...
  52. ncbi Hepatitis C virus infection in long-term nonprogressor HIV-1-infected subjects
    Vincent Thibault
    J Acquir Immune Defic Syndr 29:204-6. 2002
  53. ncbi PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status
    Delphine Sauce
    Cellular Immunology Laboratory, INSERM U543, Avenir Group, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie Paris 6, Paris, France
    AIDS 21:2005-13. 2007
    ..Assessing PD-1 expression on T cells may be highly relevant in T-cell immunology and vaccine monitoring. However, this requires us to gain further insights into the significance of PD-1 expression on CD8 T cells in humans...
  54. ncbi Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies
    Martine Braibant
    Universite Francois Rabelais, Tours, France
    J Acquir Immune Defic Syndr 47:274-84. 2008
    ..In addition, a higher proportion of defective clones was found among the env genes of NAb- patients (25% to 93%)-particularly those with lower viral loads and low levels of env diversity-than among those of NAb+ patients (7% to 19%)...